Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.

Abstract

BACKGROUND Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet destruction and decreased platelet production. Short-term administration of the thrombopoiesis-stimulating protein, romiplostim, has been shown to increase platelet counts in most patients with chronic ITP. We assessed the long-term administration of… (More)
DOI: 10.1016/S0140-6736(08)60203-2

Topics

9 Figures and Tables

Cite this paper

@article{Kuter2008EfficacyOR, title={Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.}, author={David J Kuter and James B Bussel and Roger M. Lyons and Vinod Pullarkat and Terry Gernsheimer and Francis Mark Senecal and Louis M. Aledort and J. Nicholas George and Craig M. Kessler and Miguel Acevedo Sanz and Howard A. Liebman and Frank T Slovick and Joost T. M. de Wolf and Emmanuelle Bourgeois and Troy H. Guthrie and Adrian Newland and Jeffrey S Wasser and Solomon I Hamburg and Carlos Grande and François Lefr{\`e}re and Alan Eli Lichtin and M. Tarantino and Howard R. Terebelo and J E Viallard and Francis J Cuevas and Ronald S Go and David Henry and Robert L. Redner and Lawrence Rice and Martin R. Schipperus and D. Guo and Janet L. Nichol}, journal={Lancet}, year={2008}, volume={371 9610}, pages={395-403} }